Management of lower urinary tract symptoms (LUTS) and BPH has been central to urology for decades. Open prostatectomy is the most efficient BPH treatment for relieving symptoms and improving uroflow, but is also the most invasive and morbid. Transurethral resection of the prostate (TURP) is still the “gold standard”, but the significant morbidity rate has provoked the development of alternative minimally invasive procedures.
The aim of this study was to compare the efficacy of TURP versus less invasive treatment options, as TUVP and TUNA.
LarsonT.R.Rationale and assessment of minimally invasive approaches to benign prostatic hyperplasia therapy.Urology2002; 59: 12–6.
3.
BluteM.L., LarsonT.Minimally invasive therapies for benign prostatic hyperplasia.Urology2001; 58: 33–41.
4.
HammadehM.Y., MadaanS., SinghM., PhilpT.A 3-year follow-up of a prospective randomised trial comparing transurethral electrovaporization of the prostate with standard transurethral prostatectomy.BJU2000; 86: 648–51.
5.
McAllisterW.J., KarimO., PlailR.O.Transurethral electrovaporization of the prostate: is it any better than conventional transurethral resection of the prostate?BJU2003; 91: 211–4.
6.
ZlottaA.R., GiannakopoulosX., MaehlumO., OstremT., SchulmanC.C.Long term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers.Eur Urol2003; 44: 89–93.
7.
SchatzlG., MadersbacherS., DjavanB., LangT., MarbergerM.Two-year results of tansurethral resection of the prostate versus four “less invasive” treatment options.Eur Urol2000; 37: 695–701.
